|

Drug Combo Tackles Brain Mets in Breast Cancer

By Crystal Phend, Senior Staff Writer, MedPage Today Published: November 01, 2012 Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse Planner The combination of the biologic lapatinib (Tykerb) and capecitabine (Xeloda) chemotherapy appears to shrink brain metastases from HER2-positive breast cancer without need for…